KZR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KZR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kezar Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 10.64.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kezar Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Kezar Life Sciences's Cash-to-Debt or its related term are showing as below:
During the past 8 years, Kezar Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 10.64. And the median was 20.27.
The historical data trend for Kezar Life Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Kezar Life Sciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash-to-Debt | Get a 7-Day Free Trial | 12.29 | 25.70 | 14.84 | 13.01 | 10.64 |
Kezar Life Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash-to-Debt | Get a 7-Day Free Trial | 13.01 | 12.44 | 11.74 | 11.16 | 10.64 |
For the Biotechnology subindustry, Kezar Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Kezar Life Sciences's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Kezar Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 201.372 | / | (3.012 | + | 15.921) | |
= | 10.64 |
Kezar Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 201.372 | / | (3.012 | + | 15.921) | |
= | 10.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kezar Life Sciences (NAS:KZR) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Kezar Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Morningside Venture Investments Ltd | 10 percent owner | MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
Nicholas Michael Mordwinkin | officer: Chief Business Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Wallace Courtney | director | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Micki Klearman | director | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Equal Talent Investments Ltd | 10 percent owner | THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000 |
Noreen Henig | officer: Chief Medical Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
John Franklin Fowler | director, officer: CEO | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Christopher J. Kirk | director, officer: President and CSO | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Marc Belsky | officer: Chief Financial Officer | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Vassiliki Economides | officer: SVP, Strategy & External Aff. | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Elizabeth Garner | director | 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Gp, Llc | 10 percent owner | 100 HIGH STREET, SUITE 1105, BOSTON DC 02110 |
Bay City Capital Llc | 10 percent owner | 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111 |
From GuruFocus
By Business Wire • 08-31-2023
By Business Wire Business Wire • 08-11-2022
By Business Wire • 10-09-2023
By Business Wire • 11-21-2023
By Business Wire Business Wire • 07-11-2022
By Business Wire Business Wire • 02-06-2023
By Business Wire Business Wire • 05-11-2023
By Business Wire • 09-20-2023
By Business Wire Business Wire • 03-01-2023
By Business Wire • 08-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.